US2012295898A1PendingUtilityA1

Antiviral Therapy

48
Assignee: UNDERWOOD MARK RICHARDPriority: Jan 27, 2010Filed: Jan 24, 2011Published: Nov 22, 2012
Est. expiryJan 27, 2030(~3.5 yrs left)· nominal 20-yr term from priority
Inventors:Mark Richard Underwood
A61P 31/00A61P 31/18A61P 31/12A61P 37/04A61P 43/00A61K 9/0014A61K 9/0019A61K 9/0053A61K 31/5365A61K 31/505A61K 31/536A61K 2121/00A61K 45/06A61K 31/4985A61K 31/52A61K 31/513A61K 31/675A61K 2300/00
48
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Claims

exact text as granted — not AI-modified
1 . A combination comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, with one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir. 
     
     
         2 . A combination according to  claim 1  wherein the therapeutic agent is abacavir. 
     
     
         3 . A combination according to  claim 1  wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt. 
     
     
         4 . A combination according to  claim 2  additionally containing lamivudine. 
     
     
         5 . A method of treatment of HIV infection comprising administering to a human, a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, with one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir. 
     
     
         6 . A method according to  claim 5  wherein the therapeutic agent is abacavir. 
     
     
         7 . A method according to  claim 5  wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt. 
     
     
         8 . A method according to  claim 6  additionally containing lamivudine. 
     
     
         9 . A pharmaceutical composition comprising a compound of formula (I) according to  claim 1  and one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir together with a pharmaceutically acceptable carrier therefor. 
     
     
         10 . A pharmaceutical composition according to  claim 9  wherein the therapeutic agent is abacavir. 
     
     
         11 . A pharmaceutical composition according to  claim 9  wherein the pharmaceutically acceptable salt of a compound of formula (I) is the sodium salt. 
     
     
         12 . A pharmaceutical composition according to  claim 10  additionally containing lamivudine. 
     
     
         13 . A combination according to  claim 1  wherein the combination is administered simultaneously. 
     
     
         14 . A combination according to  claim 1  wherein the combination is administered sequentially. 
     
     
         15 . A method of treatment according to  claim 5  wherein the compound of formula (I) and the therapeutic agent(s) are administered simultaneously. 
     
     
         16 . A method of treatment according to  claim 5  wherein the compound of formula (I) and the therapeutic agent(s) are administered sequentially. 
     
     
         17 . A patient pack comprising a compound of formula (I) according to  claim 1  and one or more therapeutic agents selected from the group consisting of abacavir, efavirenz, and lopinavir.

Join the waitlist — get patent alerts

Track US2012295898A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.